• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Zhengye Biotechnology Holding Limited

    12/12/25 4:10:35 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYBT alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-42450

     

    Zhengye Biotechnology Holding Limited

     

    No.1 Lianmeng Road, Jilin Economic & Technical Development Zone

    Jilin City, Jilin Province, China
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒        Form 40-F ☐

     

     

     

     

     

     

    Explanatory Note

     

    Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), is furnishing its unaudited financial statements and notes for the six months ended June 30, 2025. The financial statements and notes are attached as Exhibit 99.1 to this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025 is attached as Exhibit 99.2 to this report.

     

    Exhibit Index

     

    Exhibit No.   Description
    99.1   Unaudited Consolidated Financial Statements and Notes of Zhengye Biotechnology Holding Limited for the Six Months Ended June 30, 2025 and 2024
    99.2   Management’s Discussion and Analysis of Financial Condition and Results of Operations
    101. INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Zhengye Biotechnology Holding Limited
         
    Date: December 12, 2025 By: /s/ Songlin Song
      Name:  Songlin Song
      Title: Chief Executive Officer

     

    2

     

    Get the next $ZYBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZYBT
    SEC Filings

    View All

    SEC Form 6-K filed by Zhengye Biotechnology Holding Limited

    6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    12/12/25 4:10:35 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Zhengye Biotechnology Holding Limited

    20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    7/3/25 6:30:38 AM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zhengye Biotechnology Holding Limited

    6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    5/23/25 4:05:06 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

    JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2024. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2024 was a transformational year for us, marked by strategic decisions and tough yet necessary shifts, as we navigated significant market adjustments and proactively diversified our customer base in pursuit of long-term growth. Amid global un

    7/3/25 8:30:00 AM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

    Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Annual Report"). In a

    5/23/25 4:05:00 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

    Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, today announced that the underwriter of its initial public offering (the "Offering") have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of $4.00 per ordinary share to cover over-allotments. Gross proceeds of the Company's initial public offering, including the exercise of the over-allotment, totaled $6.9 million, before deducting underwr

    1/14/25 12:00:00 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care